CD19/79b CAR-T therapy for certain B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a one-time engineered immune-cell treatment (CAR-T) made to recognize CD19 and CD79b on certain cancer cells. It may help people with specific B-cell cancers, but you must meet several health and infection-safety requirements to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re older than 6 months.
- Your cancer has CD19 or CD79b on the cancer cells (confirmed by testing).
- Your general strength is good (KPS score above 80) and you’re expected to live more than 1 month.
- Your blood count is adequate (hemoglobin over 80 g/L).
- You can safely undergo blood cell collection (cell harvest).
- You should not have uncontrolled active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This study tests a new type of CAR T-cell treatment called SHB-02-CD19 for people with B-cell cancers that have come back or not responded to at least two prior treatments. It may be an option if you cannot receive current commercial CAR T-cell therapies.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.